NClip

Psychopharmacology

7 min read

Psychopharmacology

Key Points

  • Psychopharmacology combines pharmacokinetics and pharmacodynamics to optimize psychiatric outcomes.
  • Major drug classes include antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and stimulants.
  • Nursing priorities are adherence support, side-effect detection, safety monitoring, and client-centered education.
  • Special-population dosing and interaction risk management are essential for safe practice.

Pathophysiology

Psychotropic medications target receptor and transporter pathways to alter neurotransmission in circuits governing mood, thought, behavior, arousal, and cognition. Drug response depends on both biologic target engagement and host factors, including age, organ function, genetics, comorbidity, and concurrent medications.

Clinical effects and adverse effects emerge from receptor-level actions across CNS and peripheral systems. Therefore, symptom improvement and safety monitoring must be interpreted together, not as separate processes.

Classification

  • Pharmacokinetics: What the body does to the drug (absorption, distribution, metabolism, elimination).
  • Pharmacodynamics: What the drug does to the body (receptor interaction and physiologic response).
  • Biotransformation domain: Phase I/II metabolism, especially CYP450 substrate-induction-inhibition patterns, can materially change serum exposure and adverse-effect risk.
  • Major psychotropic classes: Antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, stimulants/non-stimulants.

Nursing Assessment

NCLEX Focus

Prioritize early detection of severe adverse reactions and class-specific contraindication patterns.

  • Assess baseline symptoms, current medications, and interaction risk before initiation or dose changes.
  • Assess class-specific adverse-effect patterns (for example EPS, serotonin toxicity, lithium toxicity, sedation/fall risk).
  • Assess adherence barriers including stigma, cost, dosing burden, and side-effect distress.
  • Assess special-population factors (pediatric, older adult, pregnancy/lactation, renal/hepatic function).
  • Assess older-adult polypharmacy with formal medication reconciliation (prescribed, OTC, supplements) and Beers-criteria risk review.
  • Assess client understanding of expected onset, warning signs, and emergency escalation points.
  • Assess age-linked safety signals, including suicidality surveillance for clients younger than 25 starting or changing antidepressants.
  • Assess for behavioral activation or mixed/manic shifts after antidepressant initiation or dose adjustment.
  • Assess dietary and over-the-counter interaction risks for MAOI therapy (for example tyramine-rich foods or pseudoephedrine use).
  • Assess stimulant misuse/diversion risk and baseline cardiovascular status (blood pressure, pulse, chest pain/syncope history).

Nursing Interventions

  • Provide structured medication education using teach-back and plain language.
  • Monitor objective and subjective response trends after starts, stops, and titrations.
  • Escalate urgent adverse events immediately and implement safety precautions per protocol.
  • Coordinate lab and program-based monitoring when indicated (for example lithium levels, clozapine ANC/REMS).
  • Collaborate with prescribers to simplify regimens and improve long-term adherence.
  • Integrate Beers-informed fall-prevention education and return-demonstration/teach-back for high-risk older-adult regimens.
  • Reinforce slow tapering plans for antidepressants and benzodiazepines to reduce withdrawal risk and rebound symptoms.
  • Use syndrome-focused triage when severe reactions are suspected (for example SHIVERS pattern for serotonin toxicity, rigidity/fever for possible NMS).

Side-Effect Normalization

Dismissing distressing side effects can drive abrupt discontinuation and relapse risk.

Pharmacology

Key class highlights include EPS and metabolic effects with antipsychotics, serotonergic toxicity and discontinuation syndromes with antidepressants, narrow therapeutic monitoring with lithium, dependence and withdrawal risk with benzodiazepines, complex sedation/fall profiles with hypnotics, and cardiovascular/activation risks with stimulant therapies. Adrenergic and cholinergic receptor effects are also clinically relevant in psychiatric settings; selected agents (for example propranolol) can be used to reduce severe anxiety-related autonomic symptoms, while anticholinergic burden can worsen cognition and safety in older adults.

Antidepressants

  • SSRIs, SNRIs, NDRIs, trazodone, TCAs, and MAOIs have variable onset; meaningful mood response often requires several weeks.
  • Abrupt discontinuation can cause withdrawal syndromes (flu-like symptoms, sleep disturbance, dizziness, mood instability, shock-like sensations); tapering is standard.
  • Serotonin syndrome risk increases with serotonergic combinations; SHIVERS supports rapid bedside recognition (Shivering, Hyperreflexia, Increased temperature, Vital-sign instability, Encephalopathy, Restlessness, Sweating).
  • MAOIs carry hypertensive-crisis risk with tyramine-containing foods and sympathomimetics; severe headache, vision change, chest pain, and neurologic symptoms require emergency escalation.

Mood Stabilizer: Lithium

  • Lithium remains a core antimanic agent with narrow therapeutic range and required serum monitoring (commonly 0.6-1.2 mEq/L).
  • Lithium has antisuicidal benefit in bipolar-spectrum illness and often begins reducing manic symptoms within 1-3 weeks.
  • Toxicity can present near therapeutic dosing; early gastrointestinal and neurologic symptoms require prompt level checks, dose hold, and supportive treatment.
  • Draw lithium levels 10-12 hours after the last dose and reinforce hydration targets (about 1.5-3 L/day unless contraindicated).
  • Lithium can reduce renal concentrating ability and precipitate nephrogenic diabetes insipidus; monitor polyuria/polydipsia and renal trends.
  • In anticonvulsant mood-stabilizer pathways, valproic-acid monitoring is high-yield (typical therapeutic range 50-125 mcg/mL; toxicity risk rises above about 150 mcg/mL).
  • Interactions (for example NSAIDs, dehydration, sodium/fluid shifts) can raise lithium levels and toxicity risk.
  • Early lithium-toxicity cues include gastrointestinal upset, drowsiness, muscle weakness, ataxia, tinnitus, and increasing dilute urine output.
  • Toxicity escalation includes provider notification, dose hold, hydration support, and dialysis consideration in severe cases.

Anxiolytics and Sedative Agents

  • Benzodiazepines reduce acute anxiety and agitation but carry misuse, dependence, respiratory depression, and fall risk.
  • Combined benzodiazepine-opioid exposure can cause profound sedation, coma, and death; avoid co-prescribing when possible and monitor closely if unavoidable.
  • Long-term benzodiazepine use should not be stopped abruptly; structured tapering is required to prevent severe withdrawal.
  • Buspirone is non-benzodiazepine and nonaddictive but not PRN-effective; it requires scheduled daily dosing and delayed onset.
  • Avoid combining buspirone with MAOIs; serotonergic combinations (for example with SSRIs/SNRIs) can increase serotonin-toxicity risk.

Antipsychotics

  • First-generation agents have higher risk of EPS and tardive dyskinesia; acute dystonia can be an airway emergency.
  • Second-generation agents lower EPS risk but increase metabolic burden (weight, glucose, lipids); baseline and periodic metabolic monitoring is required.
  • Clozapine requires REMS participation with ANC monitoring because of agranulocytosis risk; fever/sore throat must be treated as urgent cues.
  • Tobacco-smoking status can alter exposure for selected antipsychotic pathways via CYP induction, so dose plans may require reassessment when smoking starts or stops.
  • Neuroleptic malignant syndrome is a rare emergency with hyperthermia and rigidity evolving over days to weeks; immediate discontinuation and supportive management are required. Associated lab cues can include elevated CPK/WBC/liver enzymes and myoglobinuria.
  • Severe NMS management may include dantrolene or bromocriptine in addition to cooling/hydration and close electrolyte-vital monitoring.
  • Persistent tardive dyskinesia may require VMAT2-pathway treatment strategies (for example deutetrabenazine or valbenazine) after antipsychotic reassessment.

Stimulants and SUD Pharmacotherapy

  • ADHD stimulants are Schedule II drugs with abuse/diversion potential; secure storage and misuse screening are essential.
  • Stimulants can raise blood pressure and heart rate and are linked to rare but serious cardiovascular events; chest pain, syncope, and exertional symptoms require urgent evaluation.
  • Common stimulant adverse effects include insomnia, appetite suppression/weight loss, abdominal pain, and headache.
  • Less common effects include motor/vocal tics and personality blunting; paradoxical worsening requires prompt prescriber reassessment.
  • In pediatric clients, monitor appetite, weight, and linear growth during stimulant titration.
  • Stimulants are contraindicated during MAOI use and within 14 days after MAOI discontinuation.
  • Escalate urgently for stimulant-related mania, psychosis, peripheral vascular symptoms, or priapism; counsel to avoid alcohol with extended-release stimulant formulations.
  • Early dose optimization often requires weekly symptom and adverse-effect checks over about 1-3 months.
  • Medication-assisted treatment for opioid and alcohol use disorders includes buprenorphine-naloxone, methadone, naltrexone, acamprosate, and disulfiram; withdrawal protocols may include benzodiazepines for alcohol withdrawal and alpha-2 agonists for autonomic symptoms.

Clinical Judgment Application

Clinical Scenario

A client recently switched antipsychotic formulation presents with jaw stiffness, neck spasms, restlessness, and difficulty speaking.

  • Recognize Cues: Acute extrapyramidal pattern after medication transition.
  • Analyze Cues: High likelihood of medication-induced adverse effect requiring urgent intervention.
  • Prioritize Hypotheses: Priority is immediate safety and reversal/mitigation of adverse reaction.
  • Generate Solutions: Activate EPS assessment protocol, notify provider, and prepare indicated treatment.
  • Take Action: Implement urgent management, monitor response, and reassess risk after intervention.
  • Evaluate Outcomes: Confirm symptom reduction and revise ongoing medication plan and education.

Graph View